×

Meta-Analysis of Neutralizing Antibody Conversion with OnabotulinumtoxinA (BOTOX®) Across Multiple Indications: Naumann M et al.

Movement Disorders
Vol. 25, No. 13, 2010, pp. 2211–2218
©2010 Movement Disorder Society
 
Autoren:
Markus Naumann, MD,   1*
Alastair Carruthers, MD,  2
Jean Carruthers, MD,  3
Sheena K. Aurora, MD,  4
Ross Zafonte, DO,  5
Susan Abu-Shakra, MD,  6
Terry Boodhoo, MS,  6
Mary Ann Miller-Messana, RN,  6
George Demos, MD,  6
Lynn James, MPH,  6
Frederick Beddingfield, MD, PhD,  6,7
Amanda VanDenburgh, PhD,  6
Mary Ann Chapman, PhD,  8
and Mitchell F. Brin, MD  6,9

 

Autoren-Details:
1    Department of Neurology, Klinikum Augsburg Neurologische Klinik, Augsburg, Germany
2   Department of Dermatology and Skin Science, University of British Columbia, Canada
3   Department of Ophthalmology and Visual Sciences, University of British Columbia, Canada
4   Swedish Pain and Headache Center, Seattle, Washington, USA
5   Harvard Medical School, Spaulding Rehabilitation Hospital Massachusetts General Hospital, Boston, Massachusetts, USA
 Allergan, Inc., Irvine, California, USA
Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, USA
8  Visage Communications, Mead, Washington, USA
Department of Neurology, University of California, Irvine, California, USA